WESTAT, INC. - PHASE I STUDY OF PHARMACOKINETICS, SAFETY AND ACCEPTABILITY OF A SINGLE DOSE OF PRETOMANID ADDED TO AN OPTIMIZED BACKGROUND REGIMEN IN CHILDREN WITH RIFAMPICIN RESISTANT TUBERCULOSIS IMPAACT 2034

On Dec 11, 2025, Department of Health and Human Services obligated $299,389 to WESTAT, INC. for phase i study of pharmacokinetics, safety and acceptability of a single dose of pretomanid added to an optimized background regimen in children with rifampicin resistant tuberculosis impaact 2034. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition. Performance is located in ROCKVILLE, MD. The contract is scheduled through Jun 30, 2026 — approximately 1 month remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.